Wednesday, 28 May 2014

Safety and efficacy of the DPP-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged =65 years

Data from this large cohort demonstrate that linagliptin is a well-tolerated and efficacious therapy for elderly patients with T2DM (Diabetes, Obesity and Metabolism)


DPP-4 inhibitors can minimize the hypoglycemic burden and enhance safety in elderly people with diabetes

Although more information is needed to reach definitive conclusions, growing evidence suggests that DPP4-I may become a valuable component in the pharmacologic management of elderly persons with T2DM (Diabetes, Obesity and Metabolism)

No comments:

Post a Comment